Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097253 · ClinicalTrials.gov registry record · Phase 1
The Effects of Smell on Mood and Physical Responses
A Phase 1 study of Depression and Anxiety, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00097253 is a Phase 1 study of Depression and Anxiety that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 56 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00097253, a Phase 1 study of Depression and Anxiety, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the body's response to relaxing and stimulating fragrances commonly used in aromatherapy.
Conditions Studied
Interventions
- BEHAVIORAL Exposure to relaxant and stimulant odors
Study Locations (1)
Ohio
- Ohio State University Institute for Biobehavioral Medicine Research - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097253
The ClinicalTrials.gov registry entry for NCT00097253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Exposure to relaxant and stimulant odors is the first listed.
NCT00097253 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00097253 about?
NCT00097253 is a clinical study titled "The Effects of Smell on Mood and Physical Responses". The purpose of this study is to examine the body's response to relaxing and stimulating fragrances commonly used in aromatherapy.
What is the current status of trial NCT00097253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2005-08. Estimated completion is 2006-03.
What conditions does trial NCT00097253 study?
This clinical trial studies the following conditions: Depression, Anxiety, Stress.
What interventions are being tested in trial NCT00097253?
The interventions under investigation include: Exposure to relaxant and stimulant odors (BEHAVIORAL).
Who is sponsoring clinical trial NCT00097253?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00097253 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.